Phase I Dose Escalation Study of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Leukemia Research - United Kingdom
doi 10.1016/j.leukres.2013.05.011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Discordant Expression of AC133 and AC141 in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogeneous Leukemia (AML)

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

A Phase II Study of Bortezomib in Combination With Pegylated Liposomal Doxorubicin for Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

Phase I Dose‐escalation Study of Volasertib in Pediatric Patients With Acute Leukemia or Advanced Solid Tumors

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2019English

A Phase I Study of Selinexor in Combination With High-Dose Cytarabine and Mitoxantrone for Remission Induction in Patients With Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2018English

Prognostic Impact of Variant Allelic Frequency of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Effectiveness of 5-Azacytidine in Older Patients With High-Risk Myelodysplastic Syndromes and Oligoblastic Acute Myeloid Leukemia: A Retrospective Analysis of the Hellenic (Greek) MDS Study Group

Journal of Geriatric Oncology
GerontologyGeriatricsOncology
2020English

CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

Management of Cytopenias During Treatment With Lenalidomide in Patients With Myelodysplastic Syndromes

The Open Leukemia Journal
2010English

Glasdegib in Combination With Cytarabine and Daunorubicin in Patients With AML or High-Risk MDS: Phase 2 Study Results

American Journal of Hematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy